PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

PEGS Boston – 17/02/2025
NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

Wilson Disease: Genetic mutation “protects” against fatty liver and ensures better prognosis

Rare Disease Day on 28 February 2019
(Vienna, 26 February 2018) Wilson Disease (copper storage disease) is a rare genetic disorder in which one or more genetic mutations disrupt copper metabolism in the liver. At some point the liver becomes incapable of eliminating copper with the bile and copper accumulates, especially in the liver, eyes and central nervous system. This results in serious liver damage and neurological problems inter alia. MedUni Vienna researchers led by hepatologist Peter Ferenci have now discovered that a recently described genetic mutation protects against fatty liver – apparently via vitamin A metabolism –and also ensures a better outcome for Wilson disease patients. In future, this finding could prove very useful in the personalised treatment of such patients.  
The gene that has been identified is “HSD17B13” which, according to Ferenci, obviously plays an important role in vitamin A metabolism. Follow-up studies are planned to establish whether Wilson Disease patients could benefit from this knowledge – and potential treatment through the administration of vitamin A. Overall, this genetic mutation was found in every fourth person (around 26%). “We can assume that the HSD17B13 gene plays a critical role in the progression of Wilson disease,” explains Ferenci. “If patients do not have this mutation, their prognosis is poorer. So, in the spirit of precision medicine, we are able to predict much more accurately how the disease will progress.
In a highly regarded study already published in the leading journal “Hepatology” in 2018, the researchers showed that the protein ATP7B, known as the “Wilson disease gene” and of which there are hundreds of mutations, did not provide any definitive information regarding prognosis.
Wilson Disease: MedUni Vienna/Vienna General Hospital is leading centre
Around 300 people in Austria suffer from this genetic disorder. Together with Yale and Heidelberg, MedUni Vienna/Vienna General Hospital is one of the leading centres for the research and treatment of the rare disease. In a Reuters ranking, gastroenterologist and hepatologist Peter Ferenci from the Department of Medicine III was ranked in third place among the world’s leading experts in Wilson disease.
Wilson disease can go undetected for years and is usually discovered by accident. The age range is huge: the youngest known case in Vienna is a two-year-old child and the oldest patient was 74 years old. Even the symptoms are diverse: the disease can be symptomless for a long time or manifest in the form of severe liver damage, Kayser-Fleischer rings in the eyes (corneal changes) and neurological problems including movement disorders such as twitching or tremor in the limbs or even slurred speech and difficulty in swallowing. “In addition to that, there are often psychiatric disorders such as compulsive behaviours through to psychosis,” adds Ferenci.
Service:  “A HSD17B13 Variant as Genetic Modifier in hepatic Wilson Disease.” Peter Ferenci, Jan Pfeifenberger, Albert Friedrich Stättermayer, Rudolf E Stauber, Claudia Willheim; Karl H Weiss, Petra Munda-Steindl, Michael Trauner, Michael Schilsky, Heinz Zoller. JHEP Reports (accepted).
“Age, sex, but not ATP7B genotype effectively influences the clinical phenotype of Wilson disease.” Peter Ferenci, Wolfgang Stremmel, Anna Szlonkowska, Ferenc Szalay, Andre Viveiros, Albert Friedrich Stättermayer, Radna Bruhe, Roderick Houwen, Tudor Pop, Rudolf Stauber, Michael Gschwantler, Jan Pfeiffenberger, Cihan Yurdaydin, Elmar Aigner, Petra Munda-Steindl, Hans-Peter Dienes, Heinz Zoller, Karl-Heinz Weiss. 2018; doi: 10.1002/hep.30280.
Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40